Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0007 • ACR Convergence 2021
Divergent Reactivities of Rheumatoid Factors and Anti-Modified Protein Antibodies Converge on IgG Epitopes
Aisha Mergaert¹, Zihao Zheng¹, Michael Denny¹, Maya Amjadi¹, Janna Bashar¹, Michael Newton¹, Vivianne Malmström², Caroline Grönwall², Sara McCoy¹ and Miriam Shelef¹, ¹University of Wisconsin, Madison, WI, ²Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA) patients often develop rheumatoid factors (RFs), antibodies that bind IgG Fc, and anti-modified protein antibodies (AMPAs), multi-reactive autoantibodies that commonly bind…
Abstract Number: 0028 • ACR Convergence 2021
Evolution of Anti-modified Protein Antibody Responses Can Be Driven by Consecutive Exposure to Different Post-translational Modifications
Mikhail Volkov, Arieke Kampstra, Karin van Schie, Tom WJ Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Besides anti-citrullinated protein antibodies (ACPA), rheumatoid arthritis patients (RA) often display autoantibody reactivities against other post-translationally modified (PTM) proteins, more specifically carbamylated and acetylated…
Abstract Number: 0044 • ACR Convergence 2021
Autoantibodies Against Malondialdehyde-modifications Promote Osteoclast Development by Reprogramming Cellular Metabolism
Koji Sakuraba¹, Akilan Krishnamurthy¹, Alexandra Circiumaru², Jitong Sun¹, Vijay Joshua¹, Heidi Wähämaa¹, Marianne Engström¹, Meng Sun¹, Xiaowei Zheng¹, Cheng Xu¹, khaled amara¹, Vivianne Malmström¹, Sergiu Catrina¹, Caroline Grönwall¹, Anca Catrina¹ and Bence Réthi¹, ¹Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden
Background/Purpose: Malondialdehyde (MDA) is a highly reactive compound generated during lipid-peroxidation in conditions associated with oxidative stress. MDA can irreversibly modify proteins (e.g. lysine, arginine…
Abstract Number: 0156 • ACR Convergence 2021
Tenosynovitis Detected by Power Doppler Ultrasound: A Differential Feature of Patients with Seronegative Rheumatoid Arthritis
Einer Sanchez Prado¹, Santiago Ruta², Laura Cuellar¹, Sebastian Magri³ and Rodrigo Garcia Salinas⁴, ¹Hospital Italiano La Plata, La Plata, Argentina, ²Hospital San Martin de La Plata, La Plata, Argentina, ³Hospital Italiano La Plata, La Plata, ⁴Hospital Italiano de La Plata, La Plata, Argentina
Background/Purpose: It is known that seronegative rheumatoid arthritis has different characteristics from seropositive RA. Objectives: To estimate the frequency of rheumatoid arthritis (RA) in a…
Abstract Number: 0268 • ACR Convergence 2021
Effect of Biologic Agents on Lipids and Cardiovascular Risk in Rheumatoid Arthritis Patients
Dimitrios Pappas¹, George Reed², Kevin Kane², Jeffrey Curtis³ and Joel Kremer⁴, ¹Columbia University, New York, NY, ²University of Massachusetts, Worcester, MA, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Albany Medical College, Latham, NY
Background/Purpose: Cardiovascular disease (CVD) risk scores incorporating measures of inflammation such as the Reynolds risk score (RRS) may be appropriate to predict CVD risk in…
Abstract Number: 0285 • ACR Convergence 2021
Risk of Cardiovascular Disease in Newly Diagnosed Rheumatoid Arthritis: A Current Risk Assessment
Reinder Raadsen¹, Romy Hansildaar¹, Maaike Heslinga², Arno van Kuijk¹ and Michael Nurmohamed³, ¹Reade, Amsterdam, Netherlands, ²Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ³Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased risk of developing, mainly ischemic cardiovascular diseases (CVD). This is partly explained by…
Abstract Number: 0459 • ACR Convergence 2021
CCN1: An Angiogenic Actor Implicated in the Structural Damages of Rheumatoid Arthritis
Jerome Avouac¹, Alexia Steelandt², Olivia Amiar², Agathe Leblond², Cindy Orvain², Anne Cauvet², Virginie Gonzalez² and Yannick Allanore¹, ¹Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France, ²INSERM U1016, Institut Cochin, Paris, France
Background/Purpose: We have previously shown that decreased expression of the deacetylase sirtuin-1 (SIRT1) contributes to the proliferative, activated and proangiogenic profile of endothelial cells (EC)…
Abstract Number: 0564 • ACR Convergence 2021
Associations of Sinusitis, Pharyngitis, and Respiratory Tract Disease Burden with Incident Rheumatoid Arthritis
Vanessa Kronzer¹, Weixing Huang², Alessandra Zaccardelli², Cynthia Crowson³, John Davis¹, Robert Vassallo¹, Tracy Doyle⁴, Elena Losina² and Jeffrey Sparks², ¹Mayo Clinic, Rochester, MN, ²Brigham and Women's Hospital, Boston, MA, ³Mayo Clinic, Eyota, MN, ⁴Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: Increasing evidence implicates respiratory mucosa in the pathogenesis of rheumatoid arthritis (RA). However, individual respiratory tract diseases, especially of the upper airways, sinuses, and…
Abstract Number: 0587 • ACR Convergence 2021
DMARD Use in Medicare Patients with Rheumatoid Arthritis and Risk of Long-Term Opioid Use
Akhil Sood¹, Yong-Fang Kuo², Jordan Westra² and Mukaila Raji², ¹University of Texas Medical Branch, League City, TX, ²University of Texas Medical Branch, Galveston, TX
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for opioid use. Disease-modifying antirheumatic drugs (DMARDs) have led to better control of disease activity.…
Abstract Number: 0655 • ACR Convergence 2021
Depression and Fatigue: Two Forgotten Associated Comorbidities in Patients with Rheumatoid Arthritis
Rosa Morlà¹, Beatriz Frade-Sosa², Núria Sapena³, Roberto Gumucio², Raimon Sanmarti² and Jose A Gomez-Puerta², ¹Hospital Universitari Clinic de Barcelona, Barcelona, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology Department, Hospital Clínic, Barcelona, Spain
Background/Purpose: Rheumatoid arthritis (RA) is frequently associated with different comorbidities. Depression and fatigue are common in RA patients with a prevalence of 17-39-%(1) and 40%(2)…
Abstract Number: 0793 • ACR Convergence 2021
Contributing Factors of Good Outcome in Difficult-to-treat Rheumatoid Arthritis: A Multicenter RA Ultrasound Prospective Observational Cohort Study in Japan
Shin-ya Kawashiri¹, Tohru Michitsuji¹, Yushiro Endo¹, Ayako Nishino¹, Toshimasa Shimizu¹, Remi Sumiyoshi¹, Tomohiro Koga¹, Naoki Iwamoto¹, Kunihiro Ichinose² and Atsushi Kawakami¹, ¹Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan
Background/Purpose: The concept of difficult-to-treat rheumatoid arthritis (D2T RA) has emerged as the greatest unmet need in recent years. We have investigated the clinical characteristics…
Abstract Number: 0810 • ACR Convergence 2021
Persistent Disease Activity Impairs Work Productivity and Non-work Activity in Recent Onset Rheumatoid Arthritis
Carol Hitchon¹, Marie-France Valois², Orit Schieir³, Susan Bartlett², Louis Bessette⁴, Gilles Boire⁵, Glen Hazlewood⁶, Edward Keystone⁷, Janet Pope⁸, Carter Thorne⁹, Diane Tin¹⁰, Vivian Bykerk¹¹ and Canadian Early Arthritis Cohort (CATCH) Investigators¹², ¹University of Manitoba, Winnipeg, MB, Canada, ²McGill University, Montréal, QC, Canada, ³Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ⁴Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰The Arthritis Program Research Group, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²Canadian Early Arthritis Cohort, Toronto, ON, Canada
Background/Purpose: Reduced work and activity productivity are significant contributors to the personal and societal costs associated with rheumatoid arthritis (RA). We sought to describe work…
Abstract Number: 0828 • ACR Convergence 2021
Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 3 Years from the SELECT-COMPARE Study
Roy Fleischmann¹, Eduardo Mysler², Louis Bessette³, Charles Peterfy⁴, Patrick DUREZ⁵, Yoshiya Tanaka⁶, Jerzy Swierkot⁷, Nasser Khan⁸, Xianwei Bu⁹, Yihan Li⁹ and In-Ho Song⁸, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Organización Medica de Investigación, Rheumatology, Buenos Aires, Argentina, ³Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁴Spire Sciences, Inc., Boca Raton, FL, ⁵Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland, ⁸AbbVie Inc., North Chicago, IL, ⁹AbbVie Inc., North Chicago
Background/Purpose: In the SELECT-COMPARE study, the Janus kinase inhibitor, upadacitinib (UPA), demonstrated significant improvement in the signs and symptoms of rheumatoid arthritis (RA) when administered…
Abstract Number: 0844 • ACR Convergence 2021
Switching Biologics and Failure to Attain Remission in the First Year Predicts bDMARD Refractory Disease in Rheumatoid Arthritis: A 15-year Follow up of the Alberta Biologics Pharmacovigilance Cohort
Stephanie Keeling¹, Britney Jones², Jill Hall³, Joanne Homik⁴, Anthony Russell¹, Luck Lukusa⁵, Sasha Bernatsky⁶ and Walter Maksymowych⁷, ¹Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, ²University of Alberta/University of Calgary, Edmonton, AB, Canada, ³Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶McGill University, Montréal, QC, Canada, ⁷Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada
Background/Purpose: A subset of patients with rheumatoid arthritis (RA) experience refractory disease and do not attain remission imparting worse long-term outcomes. We evaluated RA patients…
Abstract Number: 1004 • ACR Convergence 2021
Manipulation of B7 Family Member Expression Demonstrates Synovial Macrophage Plasticity and Possible Future Targets for Treatment of Rheumatoid Arthritis
Annabelle Small¹, Katie Williams², Antonio Ferrante³, Malcolm Smith², Susanna Proudman⁴, Helen Weedon¹ and Mihir Wechalekar⁵, ¹Flinders University, Bedford Park, Australia, ²Flinders University, Adelaide, Australia, ³SA Pathology; University of Adelaide, Adelaide, Australia, ⁴University of Adelaide, Medindie, Australia, ⁵Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, Australia
Background/Purpose: Infiltration of monocyte-derived macrophages into the synovial tissue (ST) is a hallmark of rheumatoid arthritis (RA). These infiltrating cells lead to inflammation, local joint…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].